1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid
2026-03-08 13:50:00 ET
GLP-1 drugs are all the rage on Wall Street today, with demand for these weight loss products expected to be strong for years to come. That's helped to supercharge Eli Lilly 's (NYSE: LLY) growth and its stock price. However, you might be better off with this higher-yielding drug peer, even though it doesn't compete in the GLP-1 market.
Image source: Getty Images.
Eli Lilly was second to market with a GLP-1 drug , but Mounjaro and Zepbound proved to be more effective than competing products. They are now the leading GLP-1 drugs, with 2025 revenue growth of 99% and 175%, respectively. Together, they account for 56% of Eli Lilly's top line. Eli Lilly has a lot riding on the success of these two drugs.
NASDAQ: LLY
LLY Trading
0.45% G/L:
$1005.65 Last:
627,424 Volume:
$1006 Open:
